治疗性癌症疫苗用于复发性和转移性头颈癌的管理:综述
本综述概述了复发性和转移性头颈部鳞状细胞癌(HNSCC)现有治疗模式的临床疗效,包括检查点抑制剂和靶向治疗,并详细总结了已在HNSCC中研究的多种T细胞疫苗以及正在研究用于各种恶性肿瘤的B细胞治疗性疫苗。综述认为,近期开发并在临床环境中评估的若干治疗性T细胞和B细胞疫苗提供了有前景的治疗模式,有可能改善复发性和转移性HNSCC患者的结局。
要点
- 复发性和转移性HNSCC的治疗具有挑战性,探索治疗性癌症疫苗等额外治疗模式可能提供改善结局的机会。
- 综述总结了检查点抑制剂和靶向治疗等现有治疗模式的临床疗效。
- 综述认为若干治疗性T细胞和B细胞疫苗是有前景的治疗模式,有可能改善复发性和转移性HNSCC患者的结局。
核心结论
- 综述认为,近期开发并在临床环境中评估的若干治疗性T细胞和B细胞疫苗提供了有前景的治疗模式,有可能改善复发性和转移性HNSCC患者的结局。
研究设计与样本
- 本综述概述了复发性和转移性HNSCC现有治疗模式的临床疗效,包括检查点抑制剂和靶向治疗。
- 综述详细总结了已在HNSCC中研究的多种T细胞疫苗,以及正在研究用于各种恶性肿瘤的B细胞治疗性疫苗。
主要发现
- 综述指出,复发性和转移性HNSCC的管理具有挑战性,探索治疗性癌症疫苗等额外治疗模式可能提供改善结局的机会。
- 综述总结了检查点抑制剂和靶向治疗等现有治疗模式的临床疗效。
- 综述详细总结了已在HNSCC中研究的多种T细胞疫苗以及正在研究用于各种恶性肿瘤的B细胞治疗性疫苗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Squamous cell carcinoma of the head and neck (HNSCC) is prevalent globally and in the US. Management, particularly after disease recurrence, can be challenging, and exploring additional treatment modalities, such as therapeutic cancer vaccines, may offer an opportunity to improve outcomes in this setting. OBSERVATIONS: This review provides an overview of the clinical efficacy of different treatment modalities that are currently available for the treatment of recurrent and metastatic HNSCC, including checkpoint inhibitors and targeted therapies, with a detailed summary of the numerous T-cell vaccines that have been studied in the setting of HNSCC, as well as a detailed summary of B-cell therapeutic vaccines being investigated for various malignant tumors. CONCLUSIONS AND RELEVANCE: The findings of this review suggest that several therapeutic T-cell and B-cell vaccines, which have been recently developed and evaluated in a clinical setting, offer a promising treatment modality with the potential to improve outcomes for patients with recurrent and metastatic HNSCC.
引用
- Ritter A, Koirala N, Wieland A, et al. Therapeutic Cancer Vaccines for the Management of Recurrent and Metastatic Head and Neck Cancer: A Review. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 36580281. doi:10.1001/jamaoto.2022.4264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。